IRIX Iridex Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRIX

Price (delayed)

$1.13

Market cap

$19.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.19

Enterprise value

$19.35M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 51
Relative Valuation: Rel. Valuation: 38
Relative Profitability: Rel. Profitability: 30

Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® ...

Highlights
The EPS has soared by 56% YoY and by 27% QoQ
The net income has soared by 54% YoY and by 26% QoQ
The quick ratio has declined by 14% since the previous quarter and by 9% year-on-year
The gross margin has declined by 13% year-on-year
Sector: Healthcare
Industry: Medical Devices
Website: http://www.iridex.com
Peers: MDT NVS COO STAA

Key stats

What are the main financial stats of IRIX

IRIX stock price

How has the Iridex stock price performed over time
Intraday
-3.42%
1 week
-4.24%
1 month
-3.42%
1 year
24.15%
YTD
-0.88%
QTD
-1.31%

Financial performance

How have Iridex's revenue and profit performed over time
Revenue
$52.58M
Gross profit
$18.91M
Operating income
-$2.69M
Net income
-$3.28M
Gross margin
36%
Net margin
-6.2%
Iridex's net margin has soared by 58% YoY and by 26% from the previous quarter
The net income has soared by 54% YoY and by 26% QoQ
The operating margin has surged by 52% year-on-year but it has declined by 4.1% since the previous quarter
IRIX's operating income is up by 48% year-on-year but it is down by 4.6% since the previous quarter

Price vs fundamentals

How does IRIX's price correlate with its fundamentals

Growth

What is Iridex's growth rate over time

Valuation

What is Iridex stock price valuation
P/E
N/A
P/B
4.13
P/S
0.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.37
The EPS has soared by 56% YoY and by 27% QoQ
The price to book (P/B) is 25% lower than the 5-year quarterly average of 5.5 but 15% higher than the last 4 quarters average of 3.6
IRIX's equity is down by 3.9% since the previous quarter
The stock's price to sales (P/S) is 54% less than its 5-year quarterly average of 0.8 but 23% more than its last 4 quarters average of 0.3
The revenue has increased by 8% year-on-year

Efficiency

How efficient is Iridex business performance
Iridex's ROE has soared by 78% YoY and by 40% from the previous quarter
The ROS has soared by 59% YoY and by 28% QoQ
IRIX's return on invested capital has surged by 56% year-on-year and by 25% since the previous quarter
The company's return on assets has surged by 51% YoY and by 22% QoQ

Dividends

What is IRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRIX.

Financial health

How did Iridex financials performed over time
Iridex's total assets is 20% higher than its total liabilities
Iridex's total assets has decreased by 17% YoY and by 3% QoQ
The total liabilities has declined by 14% year-on-year and by 2.8% since the previous quarter
Iridex's debt is 10% less than its equity
Iridex's debt to equity has shrunk by 86% YoY and by 2.2% QoQ
Iridex's debt has decreased by 19% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.